ABP-745 Phase II Trial Enrollment: Atom Therapeutics has enrolled the first patient in a global Phase II study of ABP-745, a ...

Patients who use NSAIDs for paradoxical gout flare prevention when starting allopurinol demonstrate greater risk for adverse ...

Gout, a painful arthritis caused by uric acid buildup, triggers flare-ups worsened by genetics, diet, alcohol, or medication.

Atom has enrolled the first patient in a multi-country Phase 2 trial of ABP-745 for treatment of painful acute gout flares.

American pole vaulter Katie Moon captured her third consecutive world title on Wednesday by edging Sandi Morris on her final ...

"Acute Gout Flare Market 2034 by DelveInsight"The report analyzes the existing treatment practices and unmet medical requirements in Acute Gout Flare. It evaluates ...

Special CallCompany ParticipantsGuido Oelkers - CEO & PresidentMatthew WinfieldConference Call ParticipantsHerbert S.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

Many mistake gout for arthritis, delaying proper treatment and worsening the condition. Gout, caused by uric acid crystal ...

One day you wake up feeling fine, and the next day you suddenly can't even walk. For most people, the pain is unbearable and ...

Gout is a painful form of arthritis caused by high uric acid levels that form sharp crystals in the joints, leading to swelling, stiffness, and intense discomfort. While genetics and medical ...

Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition. | Atom Therapeutics is touting data from ...